Resources from the same session
Top-line results from SUNRISE: A phase III, randomized, double-blind, placebo-controlled multicenter trial of bavituximab plus docetaxel in patients with previously treated stage IIIb/iv non-squamous non-small cell lung cancer
Presenter: David Spigel
Session: NSCLC, metastatic 2
Resources:
Abstract
Presentation
Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial
Presenter: Pasi Jänne
Session: NSCLC, metastatic 2
Resources:
Abstract
Presentation
Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Presenter: Charlotte Leduc
Session: NSCLC, metastatic 2
Resources:
Abstract